Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2020 | CLL treatment: discussing new data from the last 3 years

Arnon Kater • 18 Sep 2020
ERIC 2020
Chronic Lymphocytic Leukemia Leukemia

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the importance of being able to debate new research. Over the last 3 years, there has been a large number of clinical trials that have changed the treatment paradigm. Due to each country’s different regulations, it is important to discuss chronic lymphocytic leukemia (CLL) treatment. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Arnon Kater

2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023
1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023
0:53
The future of CLL treatment
Arnon Kater • 6 Oct 2023
2:17
EPCORE CLL-1: epcoritamab in patients with R/R CLL & Richter's transformation
Arnon Kater • 6 Oct 2023

Related Videos

8:40
Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia
Maria Teresa Esposito • 25 Apr 2024
1:55
Factors to consider when choosing a treatment option for patients with CLL
Piers Patten • 28 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals